Valeant Says It Could Breach Bond Pact in May If 10-Q Is Delayed

Valeant Pharmaceuticals International Inc. dodged a potential default by filing its 2015 annual report Friday. Now it faces another in two weeks.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.